Current Health to invest in coordinating in-home staffing, services. Read the announcement.
Eliminate bed bottlenecks, expand geographic reach, improve margins, and optimize 340B— without adding load to your nursing staff. We help health systems and AMCs deliver CAR-T and bispecifics safely in outpatient settings—at scale.
Scale efficiently. Expand your program, optimize your 340B discounts, and turn advanced therapies into a financial win — not just a clinical one.
Monitoring handled. Our nurses handle first-line oversight and ICANS assessments. Your clinical staff stays in the loop — not on call.
Passive care, active recovery. Patients wear our monitor and go home. We watch. They rest.
The traditional model of extended inpatient stays for CAR-T and bispecific monitoring limits access, strains capacity, and adds unnecessary cost. With the right infrastructure, most patients can be safely monitored in outpatient or home settings.
Standard of care requires 1-3 weeks of inpatient monitoring, but most hospitals have limited beds. This caps how many patients can receive life-saving therapies—and caps how fast your program can grow.
At $3,000+ per inpatient day, extended stays add $30-60K to already expensive treatments. Payers and health systems need a more sustainable model.
Only ~150 certified centers can deliver CAR-T, mainly at urban AMCs. Patients travel hundreds of miles and stay weeks away from home. We can bring therapy closer to patients.
Extending your advanced therapy program shouldn’t mean 24/7 monitoring tasks for your nursing team. Without the right infrastructure, scaling means burning out the people who deliver care.
We combine FDA-cleared continuous monitoring, AI-powered adverse event detection, and 24/7 Clinical Command Center support to enable safe outpatient delivery of advanced therapies.
Yescarta, Kymriah, Breyanzi, Tecartus, Abecma, Carvykti and emerging products
Tecvayli, Talvey, Elrexfio, Lunsumio, Columvi, Epkinly and step-up dosing protocols
Tumor-infiltrating lymphocyte therapies like Amtagvi for solid tumors
Emerging gene therapies requiring post-administration monitoring
Sarah Cannon, the nation’s largest cell therapy provider, used Current Health to scale to 90% outpatient CAR-T delivery — adding capacity for more patients without adding beds, and saving 1,200 bed days in the first 100 cases alone.
Of CAR-T patients now cared for in outpatient setting
Of patients stayed out of the hospital for at least 72 hours
Bed days saved for every outpatient case
Of patients with a clinical alarm successfully managed at home
From AMCs to regional health systems, we help you unlock the strategic and financial benefits of outpatient advanced therapy delivery, with an implementation model designed to get you to scale quickly and easily.
Free up inpatient capacity by shifting CAR-T monitoring to outpatient. Treat more patients without adding beds.
Extend your cell therapy program to satellite locations and community partners, bringing care closer to patients.
Outpatient delivery preserves 340B pricing for eligible entities, creating significant margin on high-cost therapies.
Our platform has been shown to detect signs of CRS 7 hours earlier than standard of care. Integrated ICANS assessments
Continuous monitoring and nurse support help families feel connected and informed.
Ensure consistency as you scale outpatient care models. We'll also help you measure and publish program insights.
Offload ICANS assessments, first-line monitoring, triage, and escalation to our 24/7 nurse team.
With deep experience in ED and ICU environments, our in-house team of RNs specialize in remote identification and management of adverse events following advanced therapy administration.
Support provides continuous coverage and escalation
Licensure maintained across all 50 states
Minute median alarm response time
Of patients with a clinical alarm managed at home
